Evaluation of IPO Price-Evidence from Taiwanese Biotechnology Companies
碩士 === 國立臺灣大學 === 財務金融學研究所 === 106 === Biotechnology industry being highly professional with high proportion of intangible assets possession makes it difficult to be priced accurately. This paper target on biotechnology company Initial Public Offerings pricing. Substitute negative cash flow with cer...
Main Authors: | Peng-Yu Chen, 陳芃瑀 |
---|---|
Other Authors: | 姜堯民 |
Format: | Others |
Language: | zh-TW |
Published: |
2018
|
Online Access: | http://ndltd.ncl.edu.tw/handle/zzp29g |
Similar Items
-
The effects of disclosure level of IPO Prospectus on pricing efficiency and divergence of opinion for biotechnology companies in Taiwan
by: Chen, Fabienne Y., et al. -
Banking Relationship,UnderwriterReputation and Performance-- Evidence of Taiwanese IPOs Companies
by: Yu-Jen Liu, et al.
Published: (2006) -
Advertisement Expenditures, Underwriter Reputation, Auditor Rankingand IPOs Underpricing-Evidence of Taiwanese Listed Companies-
by: CHIEN-HUNG CHEN, et al.
Published: (2008) -
Speculative bubble in IPOs: evidence from Malaysian Fixed-Price IPOs
by: Othrnan Yong
Published: (2014) -
The Ownership Structure and Performance of Taiwanese IPO Companies
by: Hui-Ting,Lin, et al.
Published: (104)